Whilst lower serum levels of adiponectin correlate with a higher risk of breast cancer [60], treating breast cancer cells with the same adipose-derived adipokine provides conflicting results depending on estrogen receptor alpha (ERα) status [75,76]. This evidence concerns the gene ESR1 and breast cancer.